Original Research
Published on 03 Apr 2025
From COPD to cancer: indacaterol’s unexpected role in combating NSCLC
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1579126
- 194 views
Type at least 3 characters
2,779 articles
Original Research
Published on 02 Apr 2025
Reversal of sorafenib resistance in hepatocellular carcinoma by curcumol: insights from network pharmacology, molecular docking, and experimental validation
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1514997
- 188 views
Original Research
Published on 02 Apr 2025
Research mapping of cannabinoids and endocannabinoid system in cancer over the past three decades: insights from bibliometric analysis
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1540619
- 204 views
Original Research
Published on 02 Apr 2025
Therapeutic potential and mechanistic insights of silibinin targeting cancer-associated fibroblasts in colorectal cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1527871
- 207 views
Original Research
Published on 02 Apr 2025
Discovery of benzethonium chloride as a potent STAT3 inhibitor for the treatment of HNSCC
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1569570
- 252 views
Original Research
Accepted on 01 Apr 2025
Elucidation of the Mechanism Underlying the Promotion of ferroptosis and Enhanced Antitumor Immunity by Citrus Polymethoxyflavones in CRC Cells
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1571178
Original Research
Published on 01 Apr 2025
New prognostic features and personalized treatment strategies of mitochondrial related genes in colorectal cancer patients
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1540767
- 188 views
Systematic Review
Published on 01 Apr 2025
Efficacy and safety of tirabrutinib monotherapy in relapsed or refractory B-cell lymphomas/leukemia: a meta-analysis
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1559056
- 306 views
Original Research
Published on 01 Apr 2025
Exploring the impact of cuproptosis on prostate cancer prognosis via RNA methylation regulation based on single cell and bulk RNA sequencing data
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1573611
- 211 views
Case Report
Published on 01 Apr 2025
Case Report: Second-line favourable effect of pembrolizumab plus chemotherapy in a patient with metastatic hepatoid adenocarcinoma of the stomach
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1387661
- 146 views
Systematic Review
Accepted on 31 Mar 2025
Global trends in resistance studies of gemcitabine and pancreatic cancer: a bibliometric and visual analysis from 2010 to 2024
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1564561
Original Research
Accepted on 31 Mar 2025
SUMOylation substrate encoding genesRelated Genes as Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma with Functional Assessment of SAF-B2
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1532658
Review
Accepted on 31 Mar 2025
SREBP2 as a central player in cancer progression: potential for targeted therapeutics
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1535691
Original Research
Accepted on 31 Mar 2025
Targeting PCNA/PARP1 axis inhibits the malignant progression of hepatocellular carcinoma
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1571786
Original Research
Accepted on 31 Mar 2025
Dehydroleucodine Exerts an Antiproliferative Effect on Human Burkitt's Lymphoma Daudi Cells via SLC7A11-mediated Ferroptosis
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1572364
Original Research
Accepted on 28 Mar 2025
Pan-cancer analysis identified CD248 as a potential target for multiple tumor types
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1554632